OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
Chi-Jung Wu, Pei‐Chang Lee, Ya‐Wen Hung, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2631-2643
Open Access | Times Cited: 36
Chi-Jung Wu, Pei‐Chang Lee, Ya‐Wen Hung, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2631-2643
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
Pei‐Chang Lee, Chi-Jung Wu, Ya‐Wen Hung, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004779-e004779
Open Access | Times Cited: 108
Pei‐Chang Lee, Chi-Jung Wu, Ya‐Wen Hung, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004779-e004779
Open Access | Times Cited: 108
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JAMA Oncology (2023) Vol. 9, Iss. 10, pp. 1423-1423
Open Access | Times Cited: 35
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JAMA Oncology (2023) Vol. 9, Iss. 10, pp. 1423-1423
Open Access | Times Cited: 35
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 34
Yujing Xin, Xinyuan Zhang, Ning Liu, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 753-764
Closed Access | Times Cited: 34
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Yujing Xin, Fei Cao, Hongcai Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Yujing Xin, Fei Cao, Hongcai Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung‐Hung Su, Chih–Horng Wu, Tsung‐Hao Liu, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 230-241
Open Access | Times Cited: 21
Tung‐Hung Su, Chih–Horng Wu, Tsung‐Hao Liu, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 230-241
Open Access | Times Cited: 21
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
Iason Psilopatis, Christos Damaskos, Anna Garmpi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2685-2685
Open Access | Times Cited: 16
Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
Qingyan Liu, Rong Li, Ling-ling LI, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
Qingyan Liu, Rong Li, Ling-ling LI, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Samantha M. Ruff, Ashish Manne, Jordan M. Cloyd, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5863-5875
Open Access | Times Cited: 13
Samantha M. Ruff, Ashish Manne, Jordan M. Cloyd, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5863-5875
Open Access | Times Cited: 13
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Yu-Chun Hsu, Po‐Ting Lin, Wei Teng, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3458-3458
Open Access | Times Cited: 4
Yu-Chun Hsu, Po‐Ting Lin, Wei Teng, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3458-3458
Open Access | Times Cited: 4
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study
Siyang Yao, Qiangsong Huang, Yan Zou, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Siyang Yao, Qiangsong Huang, Yan Zou, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients
Cheng‐Long Han, Bao‐Wen Tian, Lun‐Jie Yan, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 1957-1969
Open Access | Times Cited: 10
Cheng‐Long Han, Bao‐Wen Tian, Lun‐Jie Yan, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 1957-1969
Open Access | Times Cited: 10
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Efficacy and safety of pembrolizumab in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis
Mingyang Tang, Tao Liu, Yukun Zhang, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Mingyang Tang, Tao Liu, Yukun Zhang, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
Jiaming Shen, Xia Wang, Guangde Yang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 207-217
Open Access | Times Cited: 2
Jiaming Shen, Xia Wang, Guangde Yang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 207-217
Open Access | Times Cited: 2
Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis
Yiwen Zhou, Jingjing Li, Jieer Ying
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 568-580
Open Access | Times Cited: 2
Yiwen Zhou, Jingjing Li, Jieer Ying
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 568-580
Open Access | Times Cited: 2
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma
Zhenkun Huang, Tiejun Chen, Wenbin Li, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Zhenkun Huang, Tiejun Chen, Wenbin Li, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy.
Wei‐Fan Hsu, Hsueh‐Chou Lai, Cheng‐Kuo Chen, et al.
PubMed (2023) Vol. 13, Iss. 2, pp. 654-668
Closed Access | Times Cited: 4
Wei‐Fan Hsu, Hsueh‐Chou Lai, Cheng‐Kuo Chen, et al.
PubMed (2023) Vol. 13, Iss. 2, pp. 654-668
Closed Access | Times Cited: 4
Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors
Ning Cong, Jun Jia, Xinmu Zhang, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 6, pp. 882-897
Open Access | Times Cited: 4
Ning Cong, Jun Jia, Xinmu Zhang, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 6, pp. 882-897
Open Access | Times Cited: 4
Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review
Fares E.M. Ali, Islam M. Ibrahim, Hanan S. Althagafy, et al.
International Immunopharmacology (2024) Vol. 132, pp. 112011-112011
Closed Access | Times Cited: 1
Fares E.M. Ali, Islam M. Ibrahim, Hanan S. Althagafy, et al.
International Immunopharmacology (2024) Vol. 132, pp. 112011-112011
Closed Access | Times Cited: 1
Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
Ming Jin, Z. Gordon Jiang, Jiankang Qin, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 2309-2320
Open Access | Times Cited: 1
Ming Jin, Z. Gordon Jiang, Jiankang Qin, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 2309-2320
Open Access | Times Cited: 1
Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
I‐Cheng Lee, Yee Chao, Pei‐Chang Lee, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2014-2014
Open Access | Times Cited: 7
I‐Cheng Lee, Yee Chao, Pei‐Chang Lee, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2014-2014
Open Access | Times Cited: 7
Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
I‐Cheng Lee, Pei‐Chang Lee, Yee Chao, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2355-2355
Open Access | Times Cited: 6
I‐Cheng Lee, Pei‐Chang Lee, Yee Chao, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2355-2355
Open Access | Times Cited: 6
